CD86 and rheumatoid arthritis: Initially designed for treatment of autoimmune diseases (abatacept; approved for rheumatoid arthritis in 2005), it was mutated to induce higher avidity binding—especially for CD86—for the prophylaxis of organ rejection (belatacept; approved for renal transplantation in 2011).